Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 82.57% | 65.19% | 53.24% | 5.01% | 17.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 82.57% | 65.19% | 53.24% | 5.01% | 17.21% |
| Cost of Revenue | 150.26% | 110.86% | 68.72% | 32.12% | 2.15% |
| Gross Profit | 71.56% | 57.52% | 50.59% | 0.96% | 20.09% |
| SG&A Expenses | 28.73% | 24.11% | 34.43% | 26.05% | 22.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.49% | 32.46% | 29.02% | 17.86% | 13.05% |
| Operating Income | 751.92% | 383.56% | 240.70% | -275.55% | 34.37% |
| Income Before Tax | 285.48% | 196.03% | 102.27% | -451.62% | 2.64% |
| Income Tax Expenses | 110.72% | 109.48% | -776.59% | -638.08% | -1,268.30% |
| Earnings from Continuing Operations | 350.45% | 226.90% | 124.92% | -283.68% | 30.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 350.45% | 226.90% | 124.92% | -283.68% | 30.60% |
| EBIT | 751.92% | 383.56% | 240.70% | -275.55% | 34.37% |
| EBITDA | 1,495.73% | 563.53% | 342.93% | -178.30% | 52.73% |
| EPS Basic | 343.69% | 223.00% | 123.40% | -277.27% | 32.56% |
| Normalized Basic EPS | 283.57% | 194.90% | 113.65% | -653.05% | 2.32% |
| EPS Diluted | 334.76% | 217.69% | 120.70% | -260.05% | 33.18% |
| Normalized Diluted EPS | 276.03% | 190.85% | 110.04% | -537.97% | 4.72% |
| Average Basic Shares Outstanding | 2.55% | 2.63% | 2.72% | 2.84% | 2.49% |
| Average Diluted Shares Outstanding | 5.52% | 4.57% | 3.88% | 1.61% | 1.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |